Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. theeoe

theEoE

A novel drug candidate for the treatment of Eosinophilic Esophagitis - an innovative solution for a significant unmet medical need

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 theEoE project word cloud

Explore the words cloud of the theEoE project. It provides you a very rough idea of what is the project "theEoE" about.

healthier    offers    regurgitation    time    investing    series    possibly    revenue    necessarily    remodeling    company    indications    28    fits    uncontrolled    white    bioavailability    complications    modulation    lower    drug    approved    inflammatory    benefit    pathologies    disease    occurs    patients    esophagitis    embryo    diseases    persistent    thelitetm    patented    innovation    manufacturing    smarter    clinical    eosinophils    nausea    reduces    therapy    inflammation    blood    promotion    efficacy    payers    difficulty    polarity    proprietary    local    pain    cells    accumulate    persists    platform    injury    barriers    cure    europe2020    integrity    people    modulating    discovery    decision    environmental    allergens    thanks    tissue    wellbeing    eoe    candidate    fly    elicited    first    technologies    symptoms    revolutionary    swallowing    physicians    topical    points    toxicology    compounds    vomiting    perfectly    modifies    generating    thelial    causing    foods    health    epithelial    sustainable    treatment    progression    ip    applies    cellular    eosinophilic    risk    prioritized    spending    line    esophagus    theeoe    cell    fewer   

Project "theEoE" data sheet

The following table provides information about the project.

Coordinator		 THELIAL TECHNOLOGIES SA 

Organization address
address: PARQUE TECNOLOGICO DE CANTANHEDE, NUCLEO 4, LOTE 3
city: CANTANHEDE
postcode: 3060197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Portugal [PT]
 Project website http://www.thelial.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THELIAL TECHNOLOGIES SA PT (CANTANHEDE) coordinator 50˙000.00

Map

 Project objective

Thelial Technologies, S.A. is a revenue generating drug discovery company that applies its unique, proprietary fly embryo-based technology to find new candidate compounds for the treatment of diseases that can be addressed by cell polarity modulation. By modulating cell polarity it is possible to specifically target a series of indications, where reduced integrity of epithelial cellular barriers is a key to pathologies. Using Thelial’s patented discovery platform theLiTETM the company has identified 28 candidate compounds, of which one – theEoE has been prioritized for further development based on toxicology, efficacy, bioavailability, IP and manufacturing decision points. theEoE will be the first approved product for treatment of Eosinophilic Esophagitis (EoE). EoE is an inflammatory disease of the esophagus elicited by foods and possibly environmental allergens. It occurs when a type of white blood cells, eosinophils, accumulate in the esophagus and persists, causing local injury and inflammation. Currently, there are no specific cure for the EoE, causing patients’ reduced wellbeing due to uncontrolled and persistent symptoms (e.g. high difficulty in swallowing, pain, nausea, regurgitation, and vomiting). Thelial offers a targeted topical treatment that reduces the clinical symptoms, modifies disease progression through tissue remodeling, and increases the duration of treatment response. These features will allow physicians, patients and payers to benefit from a revolutionary new treatment with fewer side-effects, and lower risk of health complications thanks to a better management of the disease over time. By promoting a first in line targeted therapy for EoE, Thelial’s innovation project perfectly fits the “Europe2020 challenges – for a healthier EU” 1) spending smarter but not necessarily more in sustainable health systems and 2) investing in people’s health, particularly through health-promotion programmes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THEEOE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THEEOE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More